CSL Behring’s Warfarin Antidote Kcentra Gets Green Light From FDA
This article was originally published in The Pink Sheet Daily
Kcentra is approved as an effective alternative to frozen plasma when patients on chronic warfarin to avoid clots suddenly find themselves in a bleeding emergency where they need their blood to clot fast, though Kcentra is not without risks of its own.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.